Baird raised the firm’s price target on Vor Bio (VOR) to $1 from 25c and keeps a Neutral rating on the shares. The firm updated its model following the licensing of Telitacicept from RemGen for autoimmune diseases.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: